**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a retrospective chart review, four patients (2 women and 2 men) aged 27−76 years were described, who developed COVID-19 infection during treatment with methotrexate, secukinumab, mycophenolate mofetil, prednisone, rituximab or unspecified steroids for rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) or granulomatous polyangiitis (GPA) \[*time to reactions onset not stated; not all dosages, routes and outcomes stated*\].

Case 1: The 76-year-old woman, who had rheumatoid arthritis (RA) since 2006, presented with low-grade fever, headache and minimal dry cough (for 1 week) in March 2020. She had been receiving treatment with methotrexate 10mg every week and etanercept for \>10 years. She also had been receiving various other medications. On admission, a nasopharyngeal swab obtained, and PCR analysis of this swab sample was positive for SARS-CoV-2. Laboratory tests revealed platelet count of 14 7000 mm^3^, lymphocyte of 250 mm^3^, sodium of 125 mmoL, C-reactive protein of 1.2 mg/dL, erythrocyte sedimentation rate of 11 mm/hour, LDH of 228 IU/L, D-Dimer of 195 ng/mL, IL-6 of 12.8 pg/mL and procalcitonin of 0.05 ng/mL. Her viral symptoms improved without any special treatment. During hospitalisation, she did not receive etanercept or methotrexate.

Case 2: The 74-year-old man was hospitalised in March 2020 with severe dry cough, high fevers (38.9°C), shortness of breath, fatigue, myalgias and lightheadedness for 24 hours. He had a history of ankylosing spondylitis (AS), for which he had been receiving SC secukinumab 150mg every 4 weeks for 16 months. He also had been receiving various other medications. On admission, his vital signs revealed body temperature of 38.2°C, BP of 179/78 mmHg, respiration rate of 22 breaths/minute and pulse oximeter of 98% (on room air). Laboratory tests revealed platelet count of 14 1000 mm3, lymphocyte of 1150 mm3, sodium of 133 mmoL, C-reactive protein of 11.7 mg/dL, erythrocyte sedimentation rate of 54 mm/hour, LDH of 611 IU/L, ferritin of 843 ng/mL, D-Dimer of 246 ng/mL, IL-6 of 109.6 pg/mL and procalcitonin of 0.58 ng/mL. Initial chest x-ray was normal, but CT scan performed on hospital day 2 demonstrated several small areas of groundglass opacities. On hospital day 4, an elevated inflammatory markers were observed with worsening respiratory status, following which he needed mechanical ventilation. He started receiving off-label treatment with azithromycin and hydroxychloroquine for COVID-19 infection. Secukinumab was not administered throughout hospitalisation. Thereafter, he underwent tracheostomy.

Case 3: The 49-year-old man with underlying interstitial lung disease (ILD), SLE and lupus nephritis (class III/V) presented with worsening renal function and hyperkalemia and an urgent need of hamodialysis in April 2020. He had chronic kidney disease since 2017. He had received mycophenolate mofetil and high doses of prednisone until 2019. He took hydroxychloroquine for SLE. By the time of the presentation, he had been experiencing watery diarrhoea, nausea, vomiting and decreased oral intake with no abdominal pain for 10 days. Three weeks prior, he had low-grade fevers with chills and generalised myalgias. At admission, his vital signs revealed body temperature of 36.6°C, BP of 147/89mm Hg, breathing rate of 17 /min, heart rate of 133 /min and SO~2~ of 100% (on room air). Physical examination demonstrated tachycardia. Laboratory tests revealed platelet count of 33 3000 mm3, lymphocyte of 750 mm3, sodium of 139 mmoL, C-reactive protein of 1.1 mg/dL, erythrocyte sedimentation rate of 121 mm/hour, LDH of 443 IU/L, ferritin of 965.2 ng/mL, D-Dimer of 2821 ng/mL and procalcitonin of 0.91 ng/mL. He had acute worsening of chronic renal insufficiency due to dehydration secondary to watery diarrhoea. The tests were positive for SARSCoV-2. He did not receive any special treatment except for haemodialysis. After 11 days of hospitalisation, he was discharged.

Case 4: The 27-year-old woman, who was diagnosed with GPA 2 months prior presented with severe dry cough, fever and shortness of breath in April 2020. She had been receiving unspecified high dose steroids and rituximab infusion every 4 weeks from 2 months. She also had been receiving prednisone 30mg daily. At presentation, she was tachypneic and tachycardic with oxygen saturation of 75% (on room air) and respiration rate of 44 /min. She was placed on 100% non-rebreather, but with no improvement. Physical examination revealed bilateral decreased breath sound, which was consistent with chest x-ray findings of bilateral multifocal opacities. Laboratory tests revealed platelet count of 41 1000 mm3, lymphocyte of 1600 mm3, sodium of 134 mmoL, C-reactive protein of 10 mg/dL, erythrocyte sedimentation rate of 108 mm/hour, LDH of 574 IU/L, ferritin of 1601 ng/mL, D-Dimer of 435 ng/mL, IL-6 of 150 pg/mL and procalcitonin of 0.12 ng/mL. She tested positive for SARS-CoV-2, following which she received off-label treatment with azithromycin and 5-day course of hydroxychloroquine. Due to poor clinical improvement she received one dose of off-label tocilizumab 400mg. Her oxygen and inflammatory markers improved. She did not need mechanical ventilation.
